224 related articles for article (PubMed ID: 16272364)
21. Beryllium-Induced Hypersensitivity: Genetic Susceptibility and Neoantigen Generation.
Fontenot AP; Falta MT; Kappler JW; Dai S; McKee AS
J Immunol; 2016 Jan; 196(1):22-7. PubMed ID: 26685315
[TBL] [Abstract][Full Text] [Related]
22. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69.
Amicosante M; Berretta F; Rossman M; Butler RH; Rogliani P; van den Berg-Loonen E; Saltini C
Respir Res; 2005 Aug; 6(1):94. PubMed ID: 16098233
[TBL] [Abstract][Full Text] [Related]
23. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test.
Amicosante M; Deubner D; Saltini C
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):175-9. PubMed ID: 16315779
[TBL] [Abstract][Full Text] [Related]
24. Beryllium disease.
Saltini C; Amicosante M
Am J Med Sci; 2001 Jan; 321(1):89-98. PubMed ID: 11202485
[TBL] [Abstract][Full Text] [Related]
25. Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease.
Fontenot AP; Edwards DM; Chou YK; Mack DG; LaTocha D; Vandenbark AA; Burrows GG
Eur J Immunol; 2006 Apr; 36(4):930-9. PubMed ID: 16552706
[TBL] [Abstract][Full Text] [Related]
26. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP.
Sawyer RT; Parsons CE; Fontenot AP; Maier LA; Gillespie MM; Gottschall EB; Silveira L; Newman LS
Am J Respir Cell Mol Biol; 2004 Jul; 31(1):122-30. PubMed ID: 14975942
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure of HLA-DP2 and implications for chronic beryllium disease.
Dai S; Murphy GA; Crawford F; Mack DG; Falta MT; Marrack P; Kappler JW; Fontenot AP
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7425-30. PubMed ID: 20356827
[TBL] [Abstract][Full Text] [Related]
28. Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis.
Chou YK; Edwards DM; Weinberg AD; Vandenbark AA; Kotzin BL; Fontenot AP; Burrows GG
J Immunol; 2005 Apr; 174(7):4316-24. PubMed ID: 15778396
[TBL] [Abstract][Full Text] [Related]
29. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity.
Rosenman KD; Rossman M; Hertzberg V; Reilly MJ; Rice C; Kanterakis E; Monos D
Occup Environ Med; 2011 Jul; 68(7):487-93. PubMed ID: 21186201
[TBL] [Abstract][Full Text] [Related]
30. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization.
McCanlies EC; Ensey JS; Schuler CR; Kreiss K; Weston A
Am J Ind Med; 2004 Aug; 46(2):95-103. PubMed ID: 15273960
[TBL] [Abstract][Full Text] [Related]
31. Chronic beryllium disease: immune-mediated destruction with implications for organ-specific autoimmunity.
Fontenot AP; Kotzin BL
Tissue Antigens; 2003 Dec; 62(6):449-58. PubMed ID: 14617028
[TBL] [Abstract][Full Text] [Related]
32. Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells.
Amicosante M; Berretta F; Dweik R; Saltini C
Immunology; 2009 Sep; 128(1 Suppl):e462-70. PubMed ID: 19191908
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in understanding the biomolecular basis of chronic beryllium disease: a review.
McCleskey TM; Buchner V; Field RW; Scott BL
Rev Environ Health; 2009; 24(2):75-115. PubMed ID: 19658317
[TBL] [Abstract][Full Text] [Related]
34. Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease.
Snyder JA; Demchuk E; McCanlies EC; Schuler CR; Kreiss K; Andrew ME; Frye BL; Ensey JS; Stanton ML; Weston A
J R Soc Interface; 2008 Jul; 5(24):749-58. PubMed ID: 17956852
[TBL] [Abstract][Full Text] [Related]
35. HLA-DPB1 and chronic beryllium disease: a HuGE review.
McCanlies EC; Kreiss K; Andrew M; Weston A
Am J Epidemiol; 2003 Mar; 157(5):388-98. PubMed ID: 12615603
[TBL] [Abstract][Full Text] [Related]
36. BTNL2 allele associations with chronic beryllium disease in HLA-DPB1*Glu69-negative individuals.
Sato H; Spagnolo P; Silveira L; Welsh KI; du Bois RM; Newman LS; Maier LA
Tissue Antigens; 2007 Dec; 70(6):480-6. PubMed ID: 17927685
[TBL] [Abstract][Full Text] [Related]
37. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
[TBL] [Abstract][Full Text] [Related]
38. Identification of multiple public TCR repertoires in chronic beryllium disease.
Bowerman NA; Falta MT; Mack DG; Wehrmann F; Crawford F; Mroz MM; Maier LA; Kappler JW; Fontenot AP
J Immunol; 2014 May; 192(10):4571-80. PubMed ID: 24719461
[TBL] [Abstract][Full Text] [Related]
39. To Be2+ or not to Be2+: immunogenetics and occupational exposure.
Newman LS
Science; 1993 Oct; 262(5131):197-8. PubMed ID: 8105535
[No Abstract] [Full Text] [Related]
40. HLA-DPB polymorphisms: Glu 69 association with sarcoidosis.
Lympany PA; Petrek M; Southcott AM; Newman Taylor AJ; Welsh KI; du Bois RM
Eur J Immunogenet; 1996 Oct; 23(5):353-9. PubMed ID: 8909942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
